# Coty Inc. (COTY)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/COTY/primer

## Business Model

---
source: coverage-next-full
step: 01
type: business_model
ticker: COTY
company: Coty Inc.
generated: 2026-05-28
---

### Step 01 — Business Model

#### Key Findings

- COTY operates a **licensed-fragrance + mass-color hybrid** business: ~63–65% of FY25 revenue comes from Prestige (license-heavy designer fragrance houses, plus owned prestige skincare); ~35–37% comes from Consumer Beauty (mass color cosmetics, mass fragrance, and Brazil) [S1][S3].
- The value-chain logic is **asset-light at the brand-IP layer** (Coty does not own most prestige brand IP; it licenses it from designer houses like Burberry, Hugo Boss, Gucci, Calvin Klein, and Marc Jacobs) but **asset-heavy at the formulation + fragrance-creation + packaging + global distribution layer** (Coty owns the perfumer relationships, contract-manufacturing relationships, and the global retail distribution network) [S3].
- The September 2025 strategic announcement explicitly **integrates Prestige Beauty + Mass Fragrance into a single global Fragrance & Beauty unit**, signaling that the next form factor of Coty is a fragrance-pure-play with skincare optionality — and that Consumer Beauty (mass color) is up for partnerships, divestitures, spin-offs, or other strategic alternatives [S2].
- **Net: positive for thesis.** The business model becomes more focused, more defensible, and structurally exposed to the fastest-growing beauty subsegment if Consumer Beauty is carved out.

#### Implications for Thesis and Valuation

- The fragrance license model is **scale-dependent**: economic moat comes from being the operating partner of choice for designer houses that lack in-house fragrance-creation, perfumer relationships, and global distribution. Coty's ability to renew Burberry (extended in 2023) and Hugo Boss (extended in 2024) is the single most important determinant of long-term enterprise value.
- The strategic-review optionality on Consumer Beauty is the **largest near-term value-creation lever** outside of license renewal. A successful divestiture would simplify the equity story toward an "Inter Parfums + scale" framing (~12–14x EV/EBITDA) versus the current ~7x multiple of the conglomerate.
- The owned-brand prestige skincare push (Lancaster, philosophy, Orveda — and possibly the SKKN/Kylie portfolio long term) is the **optionality at the top end** but is not yet scaled enough to materially move valuation.

#### Objective

Describe Coty's business model — what they sell, who they sell it to, and where they sit in the beauty value chain — so downstream steps on revenue architecture (Step 03), margin (Step 04), capital allocation (Step 07), and moat (Step 10) can build on a single coherent model.

#### Narrative Analysis

##### Two-segment structure

**Prestige segment (~63% of FY25 revenue, ~65% in Q3 FY26)** [S1][S3]:

- Licensed prestige fragrance houses: **Burberry, Hugo Boss, Calvin Klein, Gucci, Marc Jacobs, Chloé, Davidoff, Jil Sander, Tiffany & Co., Joop!, Marni, Naomi Campbell** (plus newer entries). Coty negotiates multi-decade licenses (typical structure: 10–20 years with renewal options), pays a royalty to the designer house, and controls the entire fragrance creation, manufacturing, marketing, and distribution stack [S3].
- Owned prestige brands: **Lancaster, philosophy, Orveda** (skincare); plus the Kylie / SKKN portfolio (license/partnership with Kim Kardashian and Kylie Jenner brands) — used as the platform for prestige skincare expansion.

**Consumer Beauty segment (~37% of FY25, ~35% Q3 FY26)** [S1][S3]:

- Mass color cosmetics: **CoverGirl, Rimmel, Max Factor, Sally Hansen, Bourjois** — mostly owned IP, distributed through drug, mass, and grocery channels.
- Mass fragrance: **Adidas, Mexx, Coty-owned licensed mass fragrances** — distributed through mass retail.
- Brazil portfolio: **Risque, Monange, Paixao, Bozzano, Biocolor** — local Brazilian brands acquired in 2012 from Hypermarcas; the largest player in Brazilian nail and locally relevant in fragrance/body. Approximately $400M of FY25 revenue [S2].

##### Value-chain map

| Layer | Coty's role | Economics |
|---|---|---|
| Brand IP | Licensee for 80%+ of prestige fragrance | Pays royalty (typically MSD–HSD% of net sales) to designer house |
| Fragrance creation | Direct relationships with master perfumers + fragrance houses (Givaudan, Firmenich, IFF, Symrise) | Cost of goods item; Coty's scale gives it pricing power vs. peers |
| Packaging design / bottle | In-house creative + external design partners | Capex-light; mostly outsourced manufacturing |
| Manufacturing | Mix of owned (e.g., Sanford, NC; Granollers, Spain) + contract manufacturers | Capex ~3% of sales; lean footprint |
| Marketing | In-house brand management + agency partnerships | High-spend item: advertising / promotion typically 25–30% of net sales |
| Sales / distribution | Direct sales forces in major markets + distributor model in smaller markets | SG&A intensive |
| Retail | Selective distribution: department stores, sephora-class specialty, travel retail (prestige); mass retail + drug + grocery (consumer beauty); growing DTC + amazon | Retailer relationships are a competitive advantage |

##### Revenue model

- **Wholesale + retail mix:** ~90%+ of revenue is wholesale to retailers (Macy's, Nordstrom, Sephora, Ulta in US; specialty + department stores internationally; mass retail for Consumer Beauty). DTC ecommerce share is growing but still a single-digit % of total revenue [S3].
- **Travel retail:** Material exposure (estimated 10%+ of prestige revenue), historically a high-margin channel; China travel-retail volatility was a meaningful 2024–2025 headwind [S3].
- **Geographic split (FY25 approximate):** EMEA largest at ~40%; Americas ~35% (US dominant); Asia-Pacific ~15%; Brazil/LatAm ~10% [S3].

##### The September 2025 reorganization

The "**integrate Prestige + Mass Fragrance**" announcement consolidates Coty's fragrance operations across price tiers into one operating engine — exploiting the fact that Coty is uniquely positioned as a top-2 player in both prestige fragrance (Burberry, Hugo Boss) and mass fragrance (Adidas, Mexx) [S2]. The thesis is that the perfumer-relationship, packaging-design, manufacturing-scale, and distribution advantages should be shared across price tiers rather than siloed.

The strategic review of Consumer Beauty (mass color + Brazil) explicitly evaluates partnerships, divestitures, spin-offs, and other actions. A spin-off would mirror what Procter & Gamble did with its beauty brands in 2016 (sold to Coty itself). A sale to a strategic (e.g., L'Oréal, Henkel) or a financial sponsor (KKR has appetite for beauty after acquiring Wella) are both plausible paths [S2].

#### Evidence and Sources

Detail in `COTY_financials/sec_filings/10K_FY2025_summary.md` and `COTY_financials/presentations/investor_presentation_2025.md`.

#### Assumption Register Updates

- A04 (Prestige ~63% of FY25 revenue) — Fact, High sensitivity (drives the segment-level valuation logic)

#### Tables and Calculations

##### Segment economic profile (FY25 illustrative, from 10-K disclosure)

| Segment | Revenue | % of total | Reported segment profit (approx) | Margin (approx) | Notes |
|---|---:|---:|---:|---:|---|
| Prestige | ~$3,700M | ~63% | ~$700M | ~19% | Fragrance leadership drives margin |
| Consumer Beauty | ~$2,190M | ~37% | ~$280M | ~13% | Mass cosmetics softness pressures margin |
| Total reported | $5,892.9M | 100% | ~$980M (segment profit before corporate) | ~17% | Reconciles to ~$1.08B adjusted EBITDA after corporate |

(Approximations; exact segment profit varies by reported vs. adjusted basis. See `COTY_financials/other/consensus.md` for the company-reported adj. EBITDA of ~$1.08B at 18.4% margin.)

##### Brand portfolio at a glance

| Tier | Brands | License vs Owned |
|---|---|---|
| Prestige fragrance — designer | Burberry, Hugo Boss, Calvin Klein, Gucci, Marc Jacobs, Chloé, Davidoff, Jil Sander, Tiffany & Co., Joop!, Marni, Naomi Campbell | Licensed |
| Prestige fragrance — owned | Lancaster heritage fragrance | Owned |
| Prestige skincare — owned | Lancaster, philosophy, Orveda | Owned |
| Prestige cosmetics — partnership | Kylie / SKKN portfolio | License/partnership |
| Mass color | CoverGirl, Rimmel, Max Factor, Sally Hansen, Bourjois | Owned |
| Mass fragrance | Adidas, Mexx, others | Mostly licensed |
| Brazil mass beauty | Risque, Monange, Paixao, Bozzano, Biocolor | Owned |

#### Open Questions and Data Gaps

1. **License expiry schedule.** Coty does not publicly disclose a full schedule of remaining license terms. Step 10 (moat) will treat this as a key risk.
2. **DTC ecommerce share growth.** Disclosed only in passing; not quantified.
3. **Per-brand revenue.** Not disclosed below segment level except for marquee licenses.

#### Next-Step Dependencies

Step 02 will use the segment + geographic mix to size the addressable market by category. Step 03 will pull the quarterly segment trajectory.

#### Source Index

| Tag | Document or URL | Section / Page | Date | Notes |
|---|---|---|---|---|
| [S1] | `COTY_financials/xbrl/xbrl_summary.md` | Annual + quarterly financials | 2026-05-28 | SEC XBRL |
| [S2] | `COTY_financials/presentations/investor_presentation_2025.md` | Strategic-review and segment narrative | 2026-05-28 | Coty press releases |
| [S3] | `COTY_financials/sec_filings/10K_FY2025_summary.md` | Business, segments, MD&A, brands | 2025-08 | Coty FY25 10-K, accession 0001024305-25-000030 |
| [S4] | `COTY_financials/industry/competitive_landscape.md` | Peer + brand category positioning | 2026-05-28 | Multiple sources aggregated |

Note: Earnings-call transcripts were intentionally not loaded (coverage-next-full path). Management commentary in this step is sourced from 8-K earnings releases (prepared-remarks summaries), press releases, and the FY25 10-K MD&A.

## Financial Snapshot

---
source: coverage-next-full
step: 04
type: financial_quality
ticker: COTY
company: Coty Inc.
generated: 2026-05-28
---

### Step 04 — Financial Quality (incl. Adversarial Sweep)

#### Key Findings

- **Earnings quality: medium.** GAAP vs. adjusted divergence is sizable (FY25 GAAP net loss $367.9M vs. adj. EBITDA $1.08B), driven primarily by **impairment charges and amortization of intangibles** [S1][S3]. Not a fabricated-earnings concern, but the adjustments are real recurring economic costs from prior acquisitions (P&G Beauty 2016).
- **Balance sheet quality: low–medium.** Goodwill $4.06B + Intangibles ex-GW $3.21B = $7.28B, **61% of total assets** [S1]. Heavy impairment exposure if discount rates rise or revenue trajectory disappoints. FY19–FY20 saw cumulative ~$5B of impairments from the P&G Beauty deal, which is the cautionary tale.
- **Adversarial sweep: clean.** No active short-seller report, no SEC investigation, no securities-fraud action of note. Industry-wide talc-related claims exist but not specifically material for COTY versus larger CPG defendants.
- **Net: mixed.** Acceptable financial quality but with explicit asset-impairment exposure that is structural to the licensed-fragrance business model (acquisitions get capitalized as intangibles/goodwill and amortize/impair over time).

#### Implications for Thesis and Valuation

- Use adjusted EBITDA as the primary cash-flow proxy, but discount it for **recurring stock-based compensation** ($50M in FY25, down from a $195M FY22 spike from CEO grant vesting), **restructuring charges** (run-rate ~$50–100M/year for cost programs), and **license-related amortization** (intangibles ex-GW amortizing ~$300–400M/year run rate).
- Free cash flow conversion has averaged ~50% of adj. EBITDA over FY22–FY25, in line with prestige beauty norms but below IPAR (~70%).
- The goodwill + intangibles base is a **valuation tail risk**, not a base-case concern. The FY25 charge mix did not show a major fresh impairment; current intangible amortization is on schedule.

#### Objective

Assess earnings quality, balance-sheet conservatism, and the disclosure environment around COTY; run an adversarial sweep for short-seller reports, regulatory actions, and known accounting controversies.

#### Narrative Analysis

##### GAAP vs. adjusted earnings reconciliation (FY25)

| Item | $M | Notes |
|---|---:|---|
| Adj. EBITDA (company-reported) | 1,084 | Per Q4 FY25 release |
| Less: D&A | (~340) | Mostly intangible amortization |
| Less: Restructuring + impairment + one-offs | (~503) | Elevated in FY25 |
| **GAAP operating income** | 241.1 | [S1] |
| Less: Interest expense | (~240) | On $4B LT debt |
| Plus / minus: Equity method (Wella + others) + FX | (~30) | Wella mark-to-market |
| Less: Tax | (~150) | Effective rate noisy due to mix and impairments |
| Plus: Discontinued operations / other | varies | |
| **GAAP net income (loss)** | (367.9) | [S1] |

The largest reconciling item between adjusted and GAAP is **impairment of intangibles and goodwill** from prior periods. The FY25 GAAP net loss of $367.9M reflects an elevated impairment year — the underlying cash earnings story is materially better than the headline net loss suggests.

##### Earnings quality flags reviewed

| Flag | Observation | Verdict |
|---|---|---|
| Aggressive revenue recognition | Standard wholesale recognition at shipment; some returns reserve volatility but no significant unusual accruals | No flag |
| Capitalization of operating costs | Capex ~$170M in FY25 (3% of sales) — modest, not aggressive | No flag |
| Inventory build vs. sales | Inventory $1.1B at FY25 end (~6.7 months of COGS) — slightly elevated but not extreme; flagged as "elevated E&O" in Q3 FY26 release | Yellow flag — inventory drag noted |
| Receivables stretch | AR $0.9B at FY25 end (~55 days) — normal | No flag |
| SBC trend | SBC normalized from FY22 $195.5M peak to FY25 $50.0M | Improving |
| Tax rate volatility | Tax rate erratic due to international mix and impairment-driven losses | Cosmetic only |
| Equity-method investment | Wella stake — historically large and variable; now monetized via Dec 2025 sale | Resolved |
| Working capital quality | DSO + DIO − DPO ~80–90 days; normal for prestige beauty | No flag |
| Off-balance-sheet | Operating leases capitalized under ASC 842; no off-BS structures of note | No flag |
| Auditor | Deloitte (long-standing) — no auditor change concerns | No flag |
| Restatement history | FY19/FY20 restatement driven by Wella deconsolidation accounting (not aggressive) | One-time |

##### Adversarial Research Sweep

This is the mandatory short-seller / litigation / investigation scan. Conducted via web search across the standard sources (Hindenburg, Muddy Waters, Citron, Spruce Point, Wolfpack, GMT Research, Kynikos, Bonitas, Hindenburg Light + general litigation databases).

| Vector | Finding | Status |
|---|---|---|
| Activist short report | **None identified** as of May 2026. Coty has not been a target of a major short report. | Clean |
| Securities-fraud class action | **None active and material** as of May 2026. | Clean |
| SEC enforcement | No active SEC enforcement actions disclosed in 10-K | Clean |
| Insider trading investigation | None | Clean |
| Talc / personal injury litigation | Industry-wide claims exist; Coty is one of many defendants but not the lead defendant (J&J / Imerys are the lead defendants industry-wide). Coty's potential exposure is well within reserves and not commented as material in 10-K | Yellow but small |
| PFAS / "forever chemicals" litigation | Industry-wide regulatory uncertainty; not a Coty-specific issue | Yellow but small |
| Patent / IP claims | Routine industry-standard claims; nothing material | Clean |
| FCPA / anti-bribery | No public investigations | Clean |
| Tax controversies | Routine ETR variability from international mix; no major IRS or OECD-level dispute disclosed | Clean |
| Board / governance | JAB's controlling stake creates structural minority-shareholder risk (related-party transactions historically clean per proxy disclosure) | Yellow structural |

**Verdict: No material adversarial findings.** Coty is structurally low-attention from short-sellers (large float, controlling shareholder, well-known industry, transparent strategic-review process).

##### Balance sheet quality (FY25 end)

| Item | $M | Comment |
|---|---:|---|
| Cash | 257.1 | Modest |
| Receivables (net) | ~870 | Normal |
| Inventory | ~1,100 | Slightly elevated; flagged by mgmt |
| PP&E (net) | ~620 | Light-asset model |
| Equity-method investment (Wella) | ~1,000 | Sold to KKR Dec 2025 for $750M cash + back-end participation |
| Goodwill | 4,062 | Mostly from P&G Beauty 2016 |
| Intangibles ex-GW | 3,215 | Designer-house licenses + acquired customer relationships |
| Other | ~785 | |
| **Total assets** | **11,908** |  |
| ST debt | ~100 | Maturity ladder is manageable |
| LT debt (noncurrent) | 3,956 | Down from $7.9B in FY20 |
| Operating lease liabilities | ~400 | |
| AP + accruals | ~1,950 | Normal |
| Other | ~1,548 | |
| **Total liabilities** | **7,952** |  |
| **Stockholders' equity** | **3,543** | Equity has been holding up despite FY25 net loss; OCI movements and SBC are the swing factors |

#### Evidence and Sources

Detail in `COTY_financials/xbrl/xbrl_summary.md` and `COTY_financials/sec_filings/10K_FY2025_summary.md`.

#### Assumption Register Updates

- A09 (Goodwill $4.06B at FY25 end) — Fact, High sensitivity to impairment risk
- A10 (Intangibles ex-GW $3.21B at FY25 end) — Fact, High sensitivity
- A11 (FY25 SBC $50M vs FY22 peak $195.5M) — Fact

#### Tables and Calculations

##### Cash flow quality (FY21–FY25)

| FY | Adj. EBITDA (approx) | CFO | Capex | FCF (CFO − Capex) | FCF / Adj. EBITDA |
|---|---:|---:|---:|---:|---:|
| 2021 | ~640 | 318.7 | (~140) | ~180 | ~28% |
| 2022 | ~900 | 726.6 | (~160) | ~567 | ~63% |
| 2023 | ~1,000 | 625.7 | (~165) | ~461 | ~46% |
| 2024 | ~1,140 | 614.6 | (~175) | ~440 | ~39% |
| 2025 | 1,084 | 492.6 | (~170) | ~323 | ~30% |

FY25 FCF conversion stepped down vs. prior years on working-capital absorption (inventory build) and lower CFO from operating profit pressure. The Q3 FY26 release flagged inventory destocking as ongoing.

##### Auditor & control environment

- Auditor: Deloitte & Touche LLP (long tenure)
- Internal control: No material weakness disclosed in FY25 10-K
- Reported restatement history: One restatement in FY19–FY20 tied to Wella deconsolidation accounting (not a quality concern)

#### Open Questions and Data Gaps

1. **Future impairment-test outcome.** Tied to discount-rate and free-cash-flow assumptions in the goodwill test. A 100-bps WACC increase could trigger a $500M+ impairment.
2. **Working capital trajectory.** If inventory normalizes, FCF conversion should recover toward 50–60%.
3. **Tax rate normalization.** Effective tax rate has been noisy due to mix and impairments; a clean run-rate is hard to anchor.

#### Next-Step Dependencies

Step 05 deepens the quarterly momentum analysis and produces the KPI sidecar. Step 06 examines the balance sheet + dilution dynamics in more depth. Step 09 will refine the ROIC framework.

#### Source Index

| Tag | Document or URL | Section / Page | Date | Notes |
|---|---|---|---|---|
| [S1] | `COTY_financials/xbrl/xbrl_summary.md` | Full P&L + balance sheet | 2026-05-28 | SEC XBRL |
| [S2] | `COTY_financials/other/consensus.md` + Coty Q3 FY26 8-K | Q3 FY26 result detail | 2026-05-05 | Accession 0001024305-26-000028 |
| [S3] | `COTY_financials/sec_filings/10K_FY2025_summary.md` | MD&A, impairment, risk factors | 2025-08 | FY25 10-K |
| [S4] | `COTY_financials/sec_filings/filing_inventory.md` | Filings list | 2026-05-28 | SEC EDGAR |
| [S5] | `COTY_financials/proxy/governance_and_compensation.md` | Audit committee + auditor disclosure | 2025-09 | DEF 14A |
| [S6] | Web search results — adversarial sweep | Short-report / litigation scan | 2026-05-28 | No material findings |

## Recent Catalysts

---
source: coverage-next-full
step: 12
type: catalysts_bull_bear
ticker: COTY
company: Coty Inc.
generated: 2026-05-28
---

### Step 12 — Catalysts / Bull vs Bear Debate

#### Key Findings

- **The defining near-term catalyst is the September-2025 strategic review of Consumer Beauty** — the binary that converts COTY from a slow-growth conglomerate into either (a) a focused prestige-fragrance pure-play trading nearer to IPAR multiples (~12–14x EV/EBITDA) or (b) an unsuccessful carve-out attempt that resets the equity narrative [S1][S2].
- **Bull thesis is structural** (fragrance category secular growth, scale + counter-positioning moat, deleveraging completion, dividend reinstatement) rather than a quick-cycle trade. **Bear thesis is operational and near-term** (mass-color erosion, tariff GM compression, license-renewal binary risk, controlling-shareholder concentration) [S2][S3].
- **The debate cannot be resolved on filings alone.** Without earnings-call transcript color, the qualitative view of "is management confident?" must be inferred from (a) the Aug-2025 CEO open-market purchase of ~272.5k shares at ~$5.50–6.50, (b) the Q3 FY26 8-K's willingness to *raise* EPS guidance while lowering EBITDA, and (c) the willingness to put Consumer Beauty under strategic review at all [S4][S5].
- **Net: actionable in both directions.** The bull case offers a credible path to ~$8–10 over 18–24 months; the bear case implies $2.50–3.00 if the strategic review fails and Prestige weakness extends.

#### Implications for Thesis and Valuation

- The bull case multiple (12–14x EBITDA) and the bear case multiple (5–6x EBITDA) bracket the entire equity range. Per-share value is enormously sensitive to which case plays out — this is the dispersion that makes COTY an opportunistic position rather than a core holding (see Step 18).
- The Q1 FY27 print (calendar Q3 2026) is the highest-conviction catalyst window: first cleanly post-tariff comparison + first quarter that should reveal strategic-review direction.
- License renewals are the single most important non-modeling discontinuity. The next material renewal events (Marc Jacobs estimated 2027–2030 window; Calvin Klein later) are far enough out to be a watch-item, not a Year-1 forecast input.

#### Objective

Stage the bull/bear analyst debate around COTY's investment case using the filings-and-consensus path (no transcripts loaded). Identify the catalysts that move the equity in each direction, and end with the 3-bullet bull and 3-bullet bear cases that feed `/complete-coverage` Step 15 and the public `/stocks/{ticker}` page.

#### Narrative Analysis

##### How the debate sets up without transcripts

Coverage-next-full deliberately excludes earnings-call transcripts. The Step 12 analyst-debate is therefore reconstructed from:
1. **8-K prepared remarks summaries** (the press-release portion that includes management quotes and forward-looking commentary) [S3].
2. **Consensus notes** (analyst expectations, range, and rating distribution) [S4].
3. **Recent news flow** (Wella divestiture close Dec-2025; KKR full exit Q4-2025; Sept-2025 strategic review announcement) [S2][S5].
4. **Insider behavior** (Aug-2025 CEO open-market buy is the single strongest signal observed) [S6].

Where the debate would benefit from transcript color (e.g., tone on tariff pass-through, license-renewal confidence, M&A appetite), this step flags the gap rather than fabricating.

##### The bull case (structural fragrance pure-play)

| Pillar | Detail | Source |
|---|---|---|
| **Strategic-review unlock** | Sept 2025 strategic review of Consumer Beauty puts $1.6B of mass-color revenue under explicit evaluation for partnership, divestiture, or spin. A successful divestiture at 1.5x sales (~$2.4B proceeds) would (a) accelerate deleveraging to <2x, (b) lift consolidated GM ~200–400 bps, (c) re-rate the residual fragrance-led business toward IPAR's 12–14x EV/EBITDA multiple from today's ~7x [S1][S2] |
| **Fragrance category tailwind** | Global fragrance subsegment growing ~7.4% CAGR through 2031 — fastest-growing major beauty subsegment. COTY is #2 globally with ~$3.7B prestige fragrance scale. Coverage of the winning category is structural [S7] (Step 02 detail) |
| **Deleveraging completion** | Net leverage went from 8x (FY20) to 3.2x (FY25) to ~3.0x with Wella proceeds applied. Target 2.0x by CY27. Each turn of deleveraging compresses the equity-risk premium and lifts the implied multiple [S3] (Step 06/07 detail) |
| **CEO insider buy** | Aug 2025 open-market purchase of ~272,500 shares at ~$5.50–6.50/share. Sue Nabi has not sold open-market since Sept-2020 hire. This is the strongest single-insider buying signal in years [S6] |
| **Dividend reinstatement** | $0.10/year reinstated in FY25 — small in dollar terms but signal-bearing that management views deleveraging as far enough along to return cash. Yield ~2.7% on $3.74 spot. Growth-of-dividend optionality once 2.0x leverage hit [S3] |
| **Wella back-end participation** | The Dec-2025 KKR transaction includes 45% back-end participation on Wella's eventual exit. KKR has stated intent to exit Wella within 5–7 years; COTY would receive incremental proceeds — a free option not in consensus [S2] |
| **KKR exit clearing block** | KKR fully exited COTY common in late 2025 via final preferred conversion. Removes the largest non-JAB overhang. Index-fund-only float dynamic improves [S2] |

##### The bear case (mass-color erosion + tariff + binary risk)

| Pillar | Detail | Source |
|---|---|---|
| **Consumer Beauty drag persists** | Q3 FY26 LFL -10% for Consumer Beauty vs. -5% for Prestige. Mass color cosmetics is in secular share-loss to e.l.f., Charlotte Tilbury masstige, Rare Beauty, and the L'Oréal stable. If the strategic-review fails to find a willing buyer or the buyer demands a steep discount, COTY will be saddled with this drag for several more years [S3][S7] (Step 05 detail) |
| **Tariff GM compression is structural** | US tariffs on EU-manufactured prestige fragrance flagged in Q3 FY26 8-K as Q4 driver of -100 to -200 bps GM compression. Estimated $50–100M annualized headwind. If tariff regime persists, this is a permanent cost-base reshape, not a one-quarter event [S3] (Step 11 detail) |
| **License-renewal binary** | Coty does not publicly disclose the license-expiry schedule. Market color suggests Marc Jacobs is among the earlier renewals (~2027–2030). The recent loss of Lacoste (to IPAR, 2019) and Roberto Cavalli (to IPAR) shows renewals are *not* automatic. Losing a top-5 license (e.g., Hugo Boss, Burberry, Calvin Klein, Gucci, Marc Jacobs) would compress EBITDA by ~$100–200M, removing 10–20% of equity value [S8] (Step 10 detail) |
| **Middle East + China travel retail** | Q3 FY26 Middle East -140 bps revenue impact; China travel retail volatile through CY24–CY25. These compound into multi-quarter top-line drag [S3] (Step 11 detail) |
| **JAB controlling-stake structural risk** | JAB Holdings controls ~50% of Class A → controls board majority. Aligned today, but minority-shareholder protection is structurally lower than at a single-class float. Any change in JAB strategy would have no public-shareholder check [S9] (Step 08 detail) |
| **Heavy goodwill + intangibles** | $4.06B goodwill + $3.21B intangibles ex-goodwill = ~$7.3B of soft assets vs. $3.8B equity. Impairment risk is real — the 2019–2020 $5B P&G Beauty cumulative writedowns are the cautionary precedent. Strategic-review divestiture below carry value would trigger fresh impairments [S10] (Step 04/07 detail) |
| **Forecast risk from continued weakness** | FY26 EBITDA guide $838–848M vs. FY25 actual $1,084M = -22% YoY. Consensus is below the low end of guide. If FY27 cannot recover, the deleveraging math breaks down [S3] (Step 05 detail) |

##### Catalyst calendar (next 18 months)

| Window | Event | Direction | Watch points |
|---|---|---|---|
| **Aug 2026** | FY26 full-year results + FY27 guide | Tighter post-tariff visibility | First view of Q1 FY27 momentum + initial FY27 framework |
| **Sept 2026** | DEF 14A + sustainability filings | Routine | Look for JAB ownership / board composition changes |
| **CY 2026 (any quarter)** | Strategic-review outcome announcement | High-impact binary | Announced divestiture multiple; size; cash use |
| **Nov 2026** | Q1 FY27 results | First cleanly post-tariff-comparison quarter | LFL inflection; Prestige re-acceleration |
| **Feb 2027** | Q2 FY27 results | Holiday quarter momentum | Mass color trajectory if not yet divested |
| **2027** | Earliest material license renewal window | Binary | Marc Jacobs renewal terms (if disclosed) |
| **Ongoing** | Wella back-end realization | Optional | KKR's Wella-exit timing (likely 5+ years) |

##### What's priced in (from consensus)

Consensus FY26 EPS ~$0.28 vs. company guide $0.33–$0.35; analyst PT range $4–$7 (median $5–$6) on a $3.74 May-2026 spot. This implies:
- Street treats the Q3 FY26 EPS raise with skepticism (consensus below guide).
- Street is pricing in *some* strategic-review unlock but not the full pure-play re-rate.
- Street is pricing in continued license renewals (no haircut for renewal risk).

The variant view (developed in Step 16) is that Street is under-pricing the strategic-review optionality and over-emphasizing near-term mass-color drag.

##### The "if I am wrong" lens

Each side of the debate has a clean falsification trigger:
- **Bull case falsified** if: Consumer Beauty strategic review concludes without a transaction (Dec-2026 or beyond), *or* a material license is lost at renewal, *or* tariff regime escalates further.
- **Bear case falsified** if: Consumer Beauty divestiture lands at ≥1.5x sales, *or* CEO continues open-market buying through 2026, *or* Prestige LFL turns clearly positive by Q1 FY27.

#### Evidence and Sources

Detail in `COTY_financials/other/consensus.md`, `COTY_financials/presentations/investor_presentation_2025.md`, `COTY_financials/sec_filings/10K_FY2025_summary.md`, `COTY_financials/proxy/insider_transactions.md`, and `COTY_financials/industry/market_overview.md`. Earnings-call transcripts were intentionally not loaded; management-tone color is sourced from 8-K prepared remarks and press releases only.

#### Assumption Register Updates

- A27 (Strategic review outcome timing CY2026) — Estimate, High sensitivity
- A28 (License-renewal cycle clustering 1–2 majors per year) — Estimate, High sensitivity

(Both entries already present in `COTY_assumption_register.md`; no new entries this step.)

#### Tables and Calculations

##### Bull / Bear EBITDA fan (rough framing for `/complete-coverage` Step 15)

| Scenario | FY27 EBITDA range | Implied multiple | Implied equity per share | Comment |
|---|---|---|---|---|
| **Bull** (Consumer Beauty divested at 1.5x, Prestige recovers 3–5%) | $1,000–1,100M | 11–13x EV/EBITDA | ~$8–10 | Plus dividend + potential Wella back-end |
| **Base** (Mid-recovery; some strategic action but not full divestiture) | $850–950M | 7–8x EV/EBITDA | ~$4.50–5.50 | Modest re-rate as deleveraging completes |
| **Bear** (Strategic review fails; license loss; tariff persists) | $700–800M | 5–6x EV/EBITDA | ~$2.50–3.00 | Multiple compression overtakes deleveraging benefit |

(Approximate framing only. `/complete-coverage` Step 14 will produce the formal DCF + multiples grid; Step 15 will assign probabilities and an expected value.)

##### Catalyst probability framing (analyst-debate working hypothesis)

| Catalyst | Estimated probability over 18mo | Direction | Magnitude |
|---|---:|---|---|
| Consumer Beauty divestiture announced | 50% | Bull | +30–60% |
| Consumer Beauty strategic review extended / no transaction | 30% | Neutral-bear | -10–20% (multiple compression) |
| License loss at renewal | 10–15% in any given year | Bear | -15–25% per material loss |
| FY27 Prestige LFL inflection (positive turn) | 60% | Bull | +20–30% |
| Tariff regime escalation | 25% | Bear | -10–15% |
| Tariff regime de-escalation | 25% | Bull | +10–15% |
| Wella back-end realized within 24 months | 15% | Bull | +5–10% (optional upside) |
| CEO insider sale signal | <5% | Bear | High signal value if it occurred |

(Probabilities are working hypotheses for the analyst debate; `/complete-coverage` Step 15 will refine these into an expected-value scenario tree.)

#### Open Questions and Data Gaps

1. **Management's confidence on Q4 FY26 / FY27 inflection** — would benefit from earnings-call transcript color; flagged for `/complete-coverage` to consider whether re-running with transcripts is warranted.
2. **License-renewal calendar** — Coty does not publish; market color is the only source.
3. **Strategic-review divestiture process** — Coty has not disclosed timeline beyond "actively pursuing."

#### Next-Step Dependencies

Step 16 will sharpen the variant view vs. consensus. Steps 17 and 18 will close out institutional positioning and portfolio sizing. The 3-bullet bull and 3-bullet bear summaries below feed `/complete-coverage` Step 15 (scenarios) and the public `/stocks/{ticker}` page.

#### Source Index

| Tag | Document or URL | Section / Page | Date | Notes |
|---|---|---|---|---|
| [S1] | `COTY_financials/presentations/investor_presentation_2025.md` | Sept 2025 strategic-review framing | 2026-05-28 | Coty press releases |
| [S2] | Coty press release — Coty Sells Remaining Stake in Wella to KKR | Dec 2025 transaction terms | 2025-12-19 | https://investors.coty.com/news-events-and-presentations/news/news-details/2025/Coty-Sells-Remaining-Stake-in-Wella-to-KKR/default.aspx |
| [S3] | `COTY_financials/other/consensus.md` + Coty Q3 FY26 8-K | FY26 guide + Q3 commentary | 2026-05-05 | Accession 0001024305-26-000028 |
| [S4] | `COTY_financials/other/stockanalysis_summary.md` | Consensus EPS + analyst PT range | 2026-05-28 | StockAnalysis.com / WallStreetZen |
| [S5] | Coty press release — Strategic Review of Consumer Beauty + Brand Reorganization | Sept 2025 announcement | 2025-09 | Coty.com news |
| [S6] | `COTY_financials/proxy/insider_transactions.md` | Aug 2025 CEO buy detail | 2026-05-28 | SEC Form 4 + GuruFocus |
| [S7] | `COTY_financials/industry/market_overview.md` + `competitive_landscape.md` | Fragrance CAGR + mass-color dynamics | 2026-05-28 | Mordor Intelligence + Circana 2025 |
| [S8] | Step 10 (this folder) | License durability + Lacoste/Cavalli precedent | 2026-05-28 | Internal cross-ref |
| [S9] | `COTY_financials/proxy/governance_and_compensation.md` | JAB structural board control | 2025-09 | DEF 14A 0001024305-25-000052 |
| [S10] | `COTY_financials/xbrl/xbrl_summary.md` + Step 04 | Goodwill / intangibles + adversarial sweep | 2026-05-28 | SEC XBRL |

Note: Earnings-call transcripts were intentionally not loaded (coverage-next-full path). Management tone, Q&A color, and forward-looking commentary nuance are not captured here.

#### Bull Case — 3 bullets

- **Strategic-review unlock + multiple re-rate.** A Consumer Beauty divestiture at 1.5x sales (~$2.4B proceeds) accelerates deleveraging to <2x, lifts consolidated gross margin 200–400 bps, and re-rates the residual fragrance-led business toward Inter Parfums' 12–14x EV/EBITDA multiple from today's ~7x — a doubling of the equity from a $3.74 base. [S1][S2]
- **Fragrance category secular winner + scale moat.** Global fragrance is growing ~7.4% CAGR (fastest major beauty subsegment), and COTY is #2 globally with ~$3.7B of prestige fragrance scale. Scale + counter-positioning (designer houses prefer to license operationally complex global distribution) sustain a durable ~250–300 bps ROIC-over-WACC spread. [S7]
- **Deleveraging + CEO insider buy + Wella back-end.** Net leverage 8x → 3.0x → 2.0x target by CY27; CEO Sue Nabi bought ~272,500 shares open-market in Aug 2025 (no open-market sales since 2020 hire); Wella back-end participation (45% of KKR's eventual exit) is a free option that consensus is not pricing. [S3][S6]

#### Bear Case — 3 bullets

- **Consumer Beauty drag + tariff structural reset.** Q3 FY26 Consumer Beauty LFL -10% vs. Prestige -5%; US tariffs on EU-manufactured fragrance flagged as -100 to -200 bps Q4 GM compression (~$50–100M annualized). If the strategic review fails to find a buyer at reasonable multiples and tariff regime persists, COTY is saddled with mass-color erosion plus a permanently higher cost base — bear-case EBITDA $700–800M implies ~$2.50–3.00/share. [S3]
- **License-renewal binary risk.** COTY does not disclose the license-expiry schedule. Recent renewal-cycle precedents include the loss of Lacoste (to IPAR, 2019) and Roberto Cavalli — renewals are not automatic. Losing a top-5 license (Hugo Boss / Burberry / Calvin Klein / Gucci / Marc Jacobs) would remove ~$100–200M of EBITDA and 10–20% of equity value at once. [S8]
- **JAB controlling-stake + impairment overhang.** JAB Holdings controls ~50% of Class A and board majority — no public-shareholder check on strategic decisions. $4.06B goodwill + $3.21B intangibles = ~$7.3B of soft assets vs. $3.8B equity, and the 2019–2020 $5B P&G Beauty cumulative writedown precedent is unrebutted. A Consumer Beauty divestiture below carry value would trigger fresh impairments. [S9][S10]

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/coty
- Full research API: GET /api/v1/research/COTY/memo
- Coverage universe: /stocks